CA2490811A1 — Use of organic compounds
Assigned to Novartis AG · Expires 2004-01-08 · 22y expired
What this patent protects
The present invention relates to drug delivery systems, comprising an ARB or a RI, or at least two representatives selected from the group consisting of an ARB, an ACEI and a RI, or, in each case, a pharmaceutically acceptable salt thereof, for the prevention and treatment of pro…
USPTO Abstract
The present invention relates to drug delivery systems, comprising an ARB or a RI, or at least two representatives selected from the group consisting of an ARB, an ACEI and a RI, or, in each case, a pharmaceutically acceptable salt thereof, for the prevention and treatment of proliferative diseases, particularly vascular diseases. The invention furthermore relates to the use of such drug delivery systems, for preventing or treating restenosis in diabetic and non~diabetic patients, or for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter in a subject in need thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.